Recent News

• 12.03.2025 - Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
• 11.13.2025 - Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
• 11.13.2025 - Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
• 11.07.2025 - Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
• 11.04.2025 - Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
• 11.04.2025 - Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
• 11.04.2025 - Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Recent Filings

• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.13.2025 - 8-K Current report
• 11.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.05.2025 - EX-99.1 EX-99.1
• 11.05.2025 - 8-K Current report